Research programme: aza compounds - Gibson Oncology/Purdue University
Alternative Names: Azaindenoisoquinolines; IdenoisoquinolinesLatest Information Update: 28 May 2025
At a glance
- Originator National Cancer Institute (USA); Purdue University
- Developer Gibson Oncology; Purdue University
- Class Antineoplastics; Isoquinolines
- Mechanism of Action DNA topoisomerase I inhibitors; Proto-oncogene protein c-myc inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 26 Apr 2021 Aza compounds is available for licensing as of 23 Apr 2021. https://gibsononcology.com/
- 23 Apr 2021 Preclinical trials in Solid tumours in USA (unspecified route) (Gibson Oncology pipeline, April 2021)